ReviewHeliyon2024
FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Facile Synthesis of Indole-, Pyrazole-, and Indazole-Pyrrolidine Hybrids as Novel Chiral Heterocyclic Building Blocks.Molecules (Basel, Switzerland) · 2026Article
- Buchwald cross-coupling for synthesis of novel N-imidazolyl-N'-aryl ureas and application in bioassay: ADMET profiling, docking and cytotoxicity studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Direct C-H difluoromethylation of heteroaromatic compounds: emerging methods and developments through 2025.RSC advances · 2026Review
- Article
- Synthesis and Development of 3-((2,4-Difluorophenyl)Amino)Propanoic Acid Derivatives as an Antiproliferative Medicinal Chemistry Scaffold Targeting Growth Factor Receptors.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Novel pyridine-heterocycle hybrids: synthesisRSC advances · 2026Article
- Design, synthesis and biological evaluation of 2,5-diaryloxazolo[4,5-Beilstein journal of organic chemistry · 2026Article
- Oxazolo[5,4-Molecules (Basel, Switzerland) · 2025Review
- Inhibition of Kinase Activity and In Vitro Downregulation of the Protein Kinases in Lung Cancer and Cervical Cancer Cell Lines and the Identified Known Anticancer Compounds ofPlants (Basel, Switzerland) · 2025Article
- Synthesis and crystal structure of piperidinyl propanenitrile towards the preparation of piperidine based bioactive films for drug delivery applications.Scientific reports · 2025Article
- An Insight into the Structure-activity Relationship of Benzimidazole and Pyrazole Derivatives as Anticancer Agents.Current topics in medicinal chemistry · 2025Review
- Halloysite Nanotube-Based Delivery of Pyrazolo[3,4-Pharmaceutics · 2024Article
- Article
- Article
- Targeted suppression of oral squamous cell carcinoma by pyrimidine-tethered quinoxaline derivatives.RSC medicinal chemistry · 2024Article
- Enhancing generalizability and performance in drug-target interaction identification by integrating pharmacophore and pre-trained models.Bioinformatics (Oxford, England) · 2024Article
- Evaluation of Antitumor Activity of Xanthones Conjugated with Amino Acids.International journal of molecular sciences · 2024Article
- Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53.Drug design, development and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the incorporation of heterocycles increases the physical characteristics and biological activity of pharmacological molecules, heterocyclic scaffolds are commonly discovered as common cores in a wide spectrum of biologically active drugs. In the contemporary context, many heterocycles have arisen, playing vital roles in diverse pharmaceutical compounds that benefit humanity. Over 85 % of FDA-approved medication molecules contain heterocycles, and most importantly, numerous heterocyclic medicinal molecules indicate potential benefits against a range: of malignancies. The unique flexibility and dynamic core scaffold of these compounds have aided anticancer research. These medications are used to treat cancer patients by targeting particular genes, enzymes, and receptors. Aside from the drugs that are now on the market, numerous forms are being researched for their potential anti-cancer activity. Here in this review, we classified some molecules and biologically active heterocycles containing anticancer medicinal moieties approved by the FDA between 2019 and 2021 based on their use in various forms of cancer. We will focus on those that are suitable for cancer treatment, as well as the essential biochemical mechanisms of action, biological targets, synthetic methods, and inherent limiting considerations in their use.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.